Pros: Concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer

Bryan M. Rabatic, Feng Ming Kong

Research output: Contribution to journalArticle

Abstract

The debate of treating stage III, large volume non-small cell lung cancer (NSCLC) with definitive chemo-radiotherapy continues to be waged. A physically fit patient, having large volume and unresectable disease is the ideal candidate for this treatment approach. The ability of this patient population to successfully complete, and thereby benefit from an aggressive, combined treatment to improve local control and survival, drives the recommendation of treating oncologists for this approach. Until a phase III trial proves otherwise, concurrent chemo-radiotherapy will remain the ideal treatment for fit patients having large volume unresectable stage III NSCLC.

Original languageEnglish (US)
Pages (from-to)190-194
Number of pages5
JournalTranslational Lung Cancer Research
Volume5
Issue number2
DOIs
StatePublished - Apr 1 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Therapeutics
Survival
Population
Oncologists

Keywords

  • Chemoradiation
  • Non-small cell lung cancer (NSCLC)
  • Stage III

ASJC Scopus subject areas

  • Oncology

Cite this

Pros : Concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer. / Rabatic, Bryan M.; Kong, Feng Ming.

In: Translational Lung Cancer Research, Vol. 5, No. 2, 01.04.2016, p. 190-194.

Research output: Contribution to journalArticle

@article{6cb8f0f7a1144f908eac386b4ac100b2,
title = "Pros: Concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer",
abstract = "The debate of treating stage III, large volume non-small cell lung cancer (NSCLC) with definitive chemo-radiotherapy continues to be waged. A physically fit patient, having large volume and unresectable disease is the ideal candidate for this treatment approach. The ability of this patient population to successfully complete, and thereby benefit from an aggressive, combined treatment to improve local control and survival, drives the recommendation of treating oncologists for this approach. Until a phase III trial proves otherwise, concurrent chemo-radiotherapy will remain the ideal treatment for fit patients having large volume unresectable stage III NSCLC.",
keywords = "Chemoradiation, Non-small cell lung cancer (NSCLC), Stage III",
author = "Rabatic, {Bryan M.} and Kong, {Feng Ming}",
year = "2016",
month = "4",
day = "1",
doi = "10.21037/tlcr.2016.04.08",
language = "English (US)",
volume = "5",
pages = "190--194",
journal = "Translational Lung Cancer Research",
issn = "2226-4477",
publisher = "Society for Translational Medicine (STM)",
number = "2",

}

TY - JOUR

T1 - Pros

T2 - Concurrent chemo-radiotherapy remains the ideal treatment in fit patients with large volume unresectable stage III non-small cell lung cancer

AU - Rabatic, Bryan M.

AU - Kong, Feng Ming

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The debate of treating stage III, large volume non-small cell lung cancer (NSCLC) with definitive chemo-radiotherapy continues to be waged. A physically fit patient, having large volume and unresectable disease is the ideal candidate for this treatment approach. The ability of this patient population to successfully complete, and thereby benefit from an aggressive, combined treatment to improve local control and survival, drives the recommendation of treating oncologists for this approach. Until a phase III trial proves otherwise, concurrent chemo-radiotherapy will remain the ideal treatment for fit patients having large volume unresectable stage III NSCLC.

AB - The debate of treating stage III, large volume non-small cell lung cancer (NSCLC) with definitive chemo-radiotherapy continues to be waged. A physically fit patient, having large volume and unresectable disease is the ideal candidate for this treatment approach. The ability of this patient population to successfully complete, and thereby benefit from an aggressive, combined treatment to improve local control and survival, drives the recommendation of treating oncologists for this approach. Until a phase III trial proves otherwise, concurrent chemo-radiotherapy will remain the ideal treatment for fit patients having large volume unresectable stage III NSCLC.

KW - Chemoradiation

KW - Non-small cell lung cancer (NSCLC)

KW - Stage III

UR - http://www.scopus.com/inward/record.url?scp=84965047238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965047238&partnerID=8YFLogxK

U2 - 10.21037/tlcr.2016.04.08

DO - 10.21037/tlcr.2016.04.08

M3 - Article

AN - SCOPUS:84965047238

VL - 5

SP - 190

EP - 194

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

SN - 2226-4477

IS - 2

ER -